Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine.

Wang J, Li L, Yang J, Clair PM, Glenn MJ, Stephens DM, Radford DC, Kosak KM, Deininger MW, Shami PJ, Kopeček J.

Nanomedicine. 2019 Feb;16:217-225. doi: 10.1016/j.nano.2018.12.011. Epub 2019 Jan 9.

PMID:
30639670
2.

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.

Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, Ahorukomeye P, Glenn MJ, Deininger MWN, Boucher KM, Bavisotto LM, Gutierrez-Sanchez G, Kennedy TP, Marcus SG, Shami PJ.

Blood Adv. 2018 Feb 27;2(4):381-389. doi: 10.1182/bloodadvances.2017013391.

3.

Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells.

Chu TW, Kosak KM, Shami PJ, Kopeček J.

Drug Deliv Transl Res. 2014 Dec;4(5-6):389-94. doi: 10.1007/s13346-014-0209-8.

4.

An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.

Kaur I, Constance JE, Kosak KM, Spigarelli MG, Sherwin CM.

Expert Opin Drug Metab Toxicol. 2015 Jan;11(1):53-65. doi: 10.1517/17425255.2015.972934. Epub 2014 Dec 9. Review.

PMID:
25488904
5.

Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.

Kaur I, Kosak KM, Terrazas M, Herron JN, Kern SE, Boucher KM, Shami PJ.

Pharm Res. 2015 Apr;32(4):1395-406. doi: 10.1007/s11095-014-1542-9. Epub 2014 Oct 18.

6.

Targeting Glutathione S-transferase M4 in Ewing sarcoma.

Zhuo R, Kosak KM, Sankar S, Wiles ET, Sun Y, Zhang J, Ayello J, Prestwich GD, Shami PJ, Cairo MS, Lessnick SL, Luo W.

Front Pediatr. 2014 Aug 6;2:83. doi: 10.3389/fped.2014.00083. eCollection 2014.

7.

Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.

Kaur I, Terrazas M, Kosak KM, Kern SE, Boucher KM, Shami PJ.

J Pharm Pharmacol. 2013 Sep;65(9):1329-36. doi: 10.1111/jphp.12100. Epub 2013 Jul 10.

8.

The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.

Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer LK.

J Pharmacol Exp Ther. 2011 Feb;336(2):313-20. doi: 10.1124/jpet.110.174904. Epub 2010 Oct 20.

9.

JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).

Shami PJ, Maciag AE, Eddington JK, Udupi V, Kosak KM, Saavedra JE, Keefer LK.

Leuk Res. 2009 Nov;33(11):1525-9. doi: 10.1016/j.leukres.2009.01.002. Epub 2009 Feb 3.

Supplemental Content

Loading ...
Support Center